Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection.

Our findings suggest that a protective Chagas disease vaccine must have the ability to eliminate parasites before they reach organs/tissues, such as the GI tract, where once established, they become largely refractory to the induced immune response.